Voya Investment Management LLC Decreases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Voya Investment Management LLC reduced its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 84.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,313 shares of the company's stock after selling 281,664 shares during the quarter. Voya Investment Management LLC owned 0.06% of IDEAYA Biosciences worth $1,344,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new stake in IDEAYA Biosciences in the 4th quarter worth $13,385,000. FMR LLC boosted its holdings in shares of IDEAYA Biosciences by 2.6% during the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after purchasing an additional 327,498 shares during the period. Vanguard Group Inc. grew its stake in shares of IDEAYA Biosciences by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after purchasing an additional 282,936 shares during the last quarter. WCM Investment Management LLC purchased a new position in IDEAYA Biosciences during the 4th quarter valued at about $6,030,000. Finally, Adage Capital Partners GP L.L.C. raised its position in IDEAYA Biosciences by 22.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock valued at $30,842,000 after purchasing an additional 220,000 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock traded down $0.81 during mid-day trading on Friday, reaching $17.37. The stock had a trading volume of 1,191,762 shares, compared to its average volume of 985,768. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The company has a 50-day moving average price of $17.77 and a two-hundred day moving average price of $22.77. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -5.26 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the previous year, the company posted ($0.53) EPS. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on IDYA shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens reaffirmed an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.